secwatch.observer — SEC 8-K summary
======================================

Issuer:     AVENUE THERAPEUTICS, INC. (ATXI)
CIK:        0001644963
Form:       8-K
Filed at:   2022-10-18T23:59:59+00:00
Accession:  0001104659-22-109739
Event type: regulatory
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Avenue Therapeutics regains Nasdaq compliance; bid price and equity requirements satisfied; delisting matter closed
--------------------------------------------------------------------------------

- On Oct 18, 2022, Nasdaq confirmed Avenue Therapeutics met the $1.00 bid price and $2.5M stockholders' equity requirements for continued listing.
- The delisting matter is closed; the company previously faced potential delisting for non-compliance with both requirements.
- A Nasdaq Hearings Panel granted a stay through Oct 2022 to demonstrate compliance; company successfully met the conditions.
- The company is now in full compliance with all applicable Nasdaq Capital Market listing criteria.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1644963/000110465922109739/0001104659-22-109739-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1644963/000110465922109739/tm2228514d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-109739

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer